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Aims In patients with acute coronary syndrome (ACS), the higher activity of effector T-cells suggests that mechanisms
involving adaptive immunity dysregulation might play a role in coronary instability. The shedding of the functional
CD31 domain 1–5 leads to uncontrolled lymphocyte activation. In experimental models, matrix metalloproteinase-
9 (MMP-9) has been implicated in endothelial CD31 cleavage. Interestingly, higher serum levels of MMP-9 have




To assess CD31 cleavage on CD4þ T-cells, we analysed by flow cytometry CD4þ T-cells of 30 ACS, 25 stable
angina (SA) patients, and 28 controls (CTRL) using two different CD31 antibodies that specifically recognize
domain 1–5 or the non-functional membrane-proximal domain 6. The ratio between the domains was significantly
lower in ACS than in SA and CTRL (P = 0.002 ACS vs. SA; P = 0.002 ACS vs. CTRL). After stimulation with anti-
CD3/CD28, the 1–5/6 domain ratio was significantly lower in ACS than in SA (P = 0.005). ELISA of supernatants
obtained from T-cell receptor-stimulated CD4þ T-cells showed higher production of MMP-9 in ACS than in SA
(P < 0.001). CD31 domain 1–5 expression in activated CD4þ T-cells from ACS patients increased after treatment
with a specific MMP-9 inhibitor (P = 0.042).
...................................................................................................................................................................................................
Conclusion Our study suggest that enhanced MMP-9 release plays a key role in determining the cleavage and shedding of the
functional CD31 domain 1–5 in CD4þ T-cells of ACS patients. This mechanism might represent an important ther-
apeutic target to modulate T-cell dysregulation in ACS.
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The immune system is a complex network tightly modulated by sev-
eral feedback loops. Elevated soluble markers of inflammation in
patients with acute coronary syndrome (ACS) are associated with
worse outcomes and might derive from abnormalities in innate and
adaptive immunity cross-talk.
The higher plasmatic matrix metalloproteinase-9 (MMP-9) con-
centration consistently observed in ACS, affecting CD31 expression,
might explain the systemic T-cell abnormalities typical of these
patients. So, molecules such as MMP-9 and CD31, could represent
desirable molecular targets for specific anti-inflammatory treatments
and might be used as clinical biomarkers of prognosis in patients with
ACS.
Introduction
In patients with acute coronary syndrome (ACS) and systemic evi-
dence of inflammation, the higher frequency and enhanced function
of effector T-cells compared with patients with stable angina (SA)
suggests that the sudden changes leading to coronary instability
might be related to mechanisms involving dysregulation of adaptive
immunity.1–4
CD31 is a member of the immunoglobulin (Ig) superfamily of cell
adhesion molecules. It is expressed on most cells of the haemato-
poietic lineage including platelets, monocytes, neutrophils, and T-cells
and plays an important role in the inflammatory response through
the modulation of leucocyte activation, cytokine production, and the
maintenance of vascular barrier integrity.5,6 CD31 is a type I trans-
membrane glycoprotein consisting in an extracellular region com-
posed of six Ig-like homology domains, a 19-residue transmembrane
domain, and a 118-residue cytoplasmic tail.7 The biological properties
of CD31 in cellular adhesion and signalling have been mapped to spe-
cific regions of the CD31 molecule. Extracellular Ig-like domain 1–5
contains residues that are important for mediating the homophilic
CD31 interactions and that are critical for the inhibition of T-cell
receptor (TCR) signalling through the action of protein tyrosine-
phosphatases recruited by its Immunoreceptor Tyrosine-based
Inhibition Motifs (ITIMs). Thus, the cleavage and shedding of CD31
Ig-like domain 1–5 from the surface of T-cells upon activation via
their TCR prevent homophilic binding interaction and the conse-
quent activation of CD31 ITIM inhibitory pathway, finally leading to
uncontrolled lymphocyte activation.8,9
CD31 has been also implicated in the development of atheroscle-
rosis in animal models10 and of its clinical complications in humans.11
CD31 expression and function on CD4þ T-cells is transiently
reduced at the time of the acute event in patients with ACS,12 and
it might contribute to the immune dysregulation observed in this
setting.12–15
In murine experimental models, matrix metalloproteinase-9
(MMP-9) seems to be implicated in endothelial CD31 cleavage.16 Of
note, higher serum levels of MMP9 in ACS have been consistently
observed in patients with poor disease outcome and plaque vulner-
ability.17–19
In this study, we analysed the expression of CD31 functional
domain 1–5 and CD31 membrane-proximal domain 6 on circulating
T-cells from patients with ACS (non-ST-segment elevation
myocardial infarction), SA, or controls (CTRL) before and after TCR-
stimulation. We sought to investigate if the reduced CD31 expres-
sion previously observed on peripheral T-cells of ACS is caused by
cleavage and shedding of functional domain 1–5, rather than its total
absence.
We also investigated the mechanisms underlying CD31 down-
regulation in ACS by studying the role of MMP-9 in the modulation of
CD31 expression.
Methods
For a detailed description of all methods, see the Supplementary material
online, Appendix.
Study population
We enrolled 30 patients admitted to our Coronary Care Unit with a diag-
nosis of non-ST-elevation myocardial infarction (NSTEMI). As control
groups, we enrolled 25 patients with chronic SA and 28 individuals with-
out a previous history and/or current symptoms or signs of ischaemic
heart disease (CTRL). All patients gave their written informed consent.
The study has been approved by the Ethics Committee of the Catholic
University of Rome. Supplementary material online, Table S1, reports
demographic and clinical characteristics of the study population.
Statistical analysis
The continuous variables that were normally distributed, as assessed by
the Shapiro–Wilk test, were described as mean ± SD and analysed with
parametric tests. For comparisons among the three groups, we used
one-way analysis of variance (ANOVA) with Bonferroni correction. For
multiple pairwise comparisons, we used two-way ANOVA for repeated
measures, with Bonferroni correction. For between-group comparisons,
we used an unpaired Student’s t-test. To compare the means of two
related samples within groups, we used a paired samples Student’s t-test.
Data that did not follow a normal distribution were analysed by using
non-parametric test. We used the Kruskal–Wallis non-parametric
ANOVA and the Dunn’s test for comparisons among groups, and the
Friedman test for repeated measures for multiple pairwise comparisons,
as appropriate. For between-group comparisons, we used Mann–
Whitney U-test. To compare two related samples within groups, we
used the Wilcoxon test. A two-tailed P-value <0.05 was considered stat-
istically significant. Statistical analysis was performed with GraphPad
Prism version 5.00 (GraphPad Software, San Diego, CA, USA) and SPSS
version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Populations
The main features of the study populations are summarized in the
Supplementary material online, Table S1.
Baseline surface expression of CD31
domains on CD4þ T-cells
To establish whether the reduced expression of the CD31 molecule
previously observed on peripheral T-cells of ACS is restricted only
to the functional domain 1–5 or extended to the totality of its six
extracellular Ig-like domains, we performed multicolour flow
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..cytometry analysis of peripheral blood mononuclear cells (PBMCs).
We analysed PBMCs obtained from all the patients enrolled in the
study (30 ACS patients, 25 SA patients, and 28 CTRL).
We used two different CD31 antibodies specifically recognizing
either the membrane-distal Ig-like domain 1–5 (clone WM59) or the
membrane-proximal Ig-like domain 6 (clone MBC 78.2) (see the
Supplementary material online, Appendix).
As shown in Figure 1A and B, C, D31 functional domain 1–5 surface
expression on unstimulated naı̈ve (1.54 ± 0.52 in ACS, 1.99 ± 0.45 in
SA, 1.89 ± 0.50 in CTRL; P = 0.001 ACS vs. SA, P = 0.009 ACS vs.
CTRL) and memory T-cells (1.57 ± 0.55 in ACS, 2.02 ± 0.62 in SA,
1.84 ± 0.50 in CTRL; P = 0.001 ACS vs. SA, P = 0.049 ACS vs. CTRL)
was lower in ACS patients as compared with SA and CTRL.
No significant differences were observed in the expression of
CD31 domain 6 among the three study groups for both naı̈ve and
memory T-cells (Figure 1C and D). Accordingly, the ratio between
domain 1–5 and 6 in naı̈ve T-cells was significantly lower in ACS
when compared with SA and CTRL (0.73 ± 0.20 in ACS, 0.86 ± 0.10
in SA, 0.89 ± 0.20 in CTRL; P = 0.002 ACS vs. SA, P = 0.002 ACS vs.
CTRL) (Figure 1E). A similar trend was observed for memory T-cells
(0.72 ± 0.23 in ACS, 0.88 ± 0.17 in SA, 0.81 ± 0.19 in CTRL; P = 0.002
ACS vs. CTRL) (Figure 1F).
Figure 1 Basal CD31 expression on CD4þ T-cells. Flow-cytometric analysis of CD31 expression on T-cell subsets. (A, B) CD31 domain 1–5 sur-
face expression (assessed by clone WM59 median fluorescence intensity) on naı̈ve and memory CD4þ T-cells was significantly lower in acute coro-
nary syndrome than stable angina and controls. (C, D) No differences were observed among the three groups of study in CD31 domain 6 surface
expression (assessed by clone MBC78.2 median fluorescence intensity) on naı̈ve and memory T-cells. (E) Acute coronary syndrome patients showed
a reduced ratio between domain 1–5/domain 6 in naı̈ve T-cells as compared with stable angina and controls. (F) Acute coronary syndrome patients
showed a reduced ratio between domain 1–5/domain 6 in memory T-cells as compared with controls. Naı̈ve and memory CD4þ T-cells were iden-
tified as CD4þCD45RAþCD45RO- and CD4þCD45RA-CD45ROþ, respectively. Data are presented as single data points and mean 95% CI (30
acute coronary syndrome patients, 25 stable angina patients, and 28 controls were included in the analysis).
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These results suggest a selective down-regulation of the CD31
functional domain 1–5 in CD4þ T-cells from ACS patients compared
to SA and CTRL.
Surface expression of CD31 domains on
CD4þ T-cells after T-cell receptor-
stimulation
After TCR stimulation, CD31 differently modulates the expression of
its two domains on T-cells.9 Therefore, CD4þ T-cells from ACS and
SA patients were stimulated for 24 h, 72 h, and 6 days with anti-CD3/
CD28 monoclonal antibodies (mAb) and the expression of the two
CD31 domains was assessed as previously described (eight patients
for each group of study were analysed).
As shown in Figure 2A, after TCR stimulation of CD4þ T-cells, the
expression of CD31 domain 1–5 was lower in ACS than in SA (24 h:
0.97 ± 0.25 vs. 1.97 ± 0.60, P < 0.001; 72 h: 2.61 ± 1.11 vs. 4.32 ± 1.10,
P = 0.007; 6 days 2.55 ± 0.88 vs. 3.88 ± 0.97, P= 0.01). No differences
were observed in CD31 domain 6 expressions (Figure 2B). Accordingly,
the ratio between domain 1–5 and 6 in CD4þ T-cells was significantly
lower in ACS when compared with SA (24 h: 0.48 ± 0.25 vs.
0.79 ± 0.27, P = 0.03; 72 h: 0.8 ± 0.23 vs. 1.03 ± 0.30, P= 0.05; 6 days
0.72 ± 0.21 vs. 1.02 ± 0.13, P = 0.005) (Figure 2C). Soluble CD31 levels in
the supernatants of in vitro activated CD4þ T-cells, as assessed by
ELISA, were higher (although not significantly) in ACS as compared with
SA patients after 6 days of TCR stimulation (five patients for each group
of study were analysed) (Figure 2D).
All together, these results suggest that the selective down-
regulation of the CD31 functional domain 1–5 in ACS is linked to
T-cell activation.
CD31 mRNA expression in CD4þ T-cells
To quantify CD31 mRNA expression and the CD31 functional
domain 1–5 protein expression simultaneously, PrimeFlowVR RNA
Assay was performed in ACS and SA patients (five patients for each
group of study were analysed). This technique allows quantifying
mRNA expression at single cells levels by flow cytometry, avoiding
cell sorting.
PrimeFlow mRNAVR experiments revealed that both naı̈ve and
memory CD4þ T-cells, as well as CD31þ and CD31-CD4þ T-cells,
had the same CD31 mRNA level (Figure 3A and B), suggesting the
existence of a post-transcriptional mechanism of CD31 protein regu-
lation in T-cells.
After in vitro activation of TCR signalling with anti-CD3/CD28
mAb crosslink, CD31 mRNA expression significantly increased at
72 h and 6 days in both groups (P < 0.001 for both groups at 72 h and
6 days vs. basal condition), and no differences were observed
between ACS and SA patients (Figure 3C and D). These results
Figure 2 CD31 expression after T-cell receptor stimulation. CD4þ T-cells were activated in vitro with aCD3/aCD28 for T-cell receptor stimula-
tion. Cells were harvested after 24 h, 72 h, and 6 days of stimulation and CD31 domain surface expression was assessed by flow cytometry. (A)
Acute coronary syndrome showed a reduced expression of CD31 domain 1–5 on CD4þ T-cells as compared with stable angina. (B) No differences
were observed in CD31 domain 6 surface expression on CD4þ T-cells after T-cell receptor stimulation. (C) Accordingly, the ratio between domain
1–5/domain 6 was significantly lower in acute coronary syndrome when compared with stable angina. Cumulative data from eight acute coronary
syndrome and eight stable angina patients. Values are fold-increases relative to levels in untreated CD4þ T-cells (95% CI). (D) Soluble CD31 levels in
the supernatants of in vitro activated CD4þ T-cells, as assessed by ELISA, were higher (although not significantly) in acute coronary syndrome as com-
pared with stable angina patients after 6 days of T-cell receptor stimulation (five patients for each study group). Green lines and histograms: stable
angina; red lines and histograms: acute coronary syndrome. MFI, median fluorescence intensity; NT, untreated.
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support the hypothesis that the mechanism triggering CD31 down-
regulation in ACS is due to a selective loss of CD31 domain 1–5.
Matrix metalloproteinase-9 mRNA
expression in CD4þ T-cells and MMP-9
release
In order to identify CD31 cleavage sites, we used a software for the
prediction of novel substrates and their cleavage sites (see
Supplementary material online). This analysis suggested a role for
MMP-9 in CD31 cleavage, so we decided to assess the expression of
MMP-9 mRNA in CD4þ T-cells obtained from 24 ACS and 20 SA
patients. As shown in Figure 4A, ACS patients showed higher expres-
sion of MMP-9 mRNA compared with SA (860.6 ± 674.3 vs.
371.0 ± 440.1; P = 0.009).
T-cells constitutively produce small amounts of MMP-9 that are
up-regulated after activation,20 therefore we stimulated CD4þ
T-cells from ACS and SA patients with anti-CD3/CD28 mAb cross-
link and performed ELISA assay of supernatants. Acute coronary syn-
drome patients showed higher levels of MMP-9 as compared with SA
after stimulation (487 ± 260.3 pg/mL vs. 172 ± 88.8 pg/mL P < 0.001)
(Figure 4B) (six patients for each group of study were analysed).
No differences were observed between the two groups at baseline.
Effects of matrix metalloproteinase-9
inhibition on CD31 expression in CD4þ
T-cells from acute coronary syndrome
patients
To determine MMP-9 involvement in CD31 cleavage, we treated
CD4þ T-cells obtained from ACS with the specific MMP-9 inhibitor
I. As shown in Figure 5A and C, we observed an increase of CD31
domain 1–5 expression in 6 days of TCR-stimulated CD4þ T-cells
after MMP-9 inhibition (1.41 ± 0.30 vs. 3.01 ± 1.3; P = 0.042) (five
patients for each group of study were analysed). No differences were
observed in CD31 domain 6 (Figure 5B).
Role of circulating matrix
metalloproteinase-9 in CD31 cleavage
Consistent data have shown that higher serum levels of MMP-9 in
ACS are associated with poor disease outcome and plaque vulner-
ability.17–19 In order to study the role of circulating MMP-9 in CD31
Figure 3 CD31 mRNA expression in CD4þ T-cells. CD31 mRNA expression in CD4þ T-cells was assessed by PrimeFlowVR assay.
(A) Representative flow cytometric histogram plot of CD31 mRNA expression in naı̈ve and memory CD4þ T-Cells at basal level. (B) Representative
flow cytometric histogram plot of CD31 mRNA expression in CD31þ (clone WM59 to detect the CD31 membrane-distal domain 1–5) and CD31-
CD4þ T-cells at basal level. (C) Representative flow cytometric histogram plot of CD31 mRNA expression in CD4þ T-cells after TCR stimulation
with anti-CD3/CD28 antibodies. (D) Trends over time of the CD31 mRNA expression in T-cell receptor-stimulated CD4þ T-cells obtained from
acute coronary syndrome and stable angina patients (five patients for each study group). Data are presented as mean 95% CI. Green lines: stable
angina; red lines: acute coronary syndrome. *P < 0.001 compared to basal condition.
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..cleavage, we performed experiments using serum from ACS and SA
patients.
CD4þ T-cells obtained from SA and ACS patients were incubated
with serum obtained from SA or ACS patients, with or without
MMP9 inhibitor I. As shown in Figure 6A, incubation for 24 h of CD4þ
T-cells obtained from five SA patients with serum obtained from
ACS patients resulted in a reduction of CD31 domain 1–5 expression
(1.3 ± 0.28 after incubation with ACS serum vs. 1.93 ± 0.44 in basal
Figure 4 Matrix metalloproteinase-9 expression in CD4þ T-cells at baseline and after T-cell receptor stimulation. (A) Matrix metalloproteinase-9
mRNA expression was assessed by quantitative real-time polymerase chain reaction in CD4þ T-cells (20 stable angina patients and 24 acute coro-
nary syndrome patients were included). Data are presented as single data points, mean 95% CI. (B) Matrix metalloproteinase-9 protein levels were
assessed by ELISA in the supernatants of CD4þ T-cells at baseline and after 6 days of T-cell receptor stimulation (five patients for each group of
study). Data are presented as mean 95% CI. Green histograms: stable angina; Red histograms: acute coronary syndrome. MFI, median fluorescence
intensity; NT, untreated.
Figure 5 Effects of matrix metalloproteinase-9 inhibition on CD31 expression in CD4þ T-cells from acute coronary syndrome patients. CD4þ
T-cells were stimulated for 6 days with anti-CD3/CD28 monoclonal antibodies with or without matrix metalloproteinase-9 inhibitor I. (A, B)
Representative flow cytometric histogram plots of CD31 domain 1–5 and CD31 domain 6 surface expression on T-cell receptor-stimulated CD4þ
T-cells before and after matrix metalloproteinase-9 inhibition. (C) CD31 domain 1–5 surface expression on T-cell receptor-stimulated CD4þ T-cells
from five acute coronary syndrome patients before and after matrix metalloproteinase-9 inhibitions. After matrix metalloproteinase-9 inhibitions,
activated CD4þ T-cells showed a higher expression of CD31 domain 1–5. Data are presented as mean 95% CI. MFI, median fluorescence intensity.
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condition, P = 0.023). This reduction was not anymore observed
when MMP-9 inhibitor was added to the cell cultures. In the same
experimental conditions, when CD4þ T-cells from five ACS patients
were incubated with serum obtained from SA or ACS patients, and
with or without MMP9 inhibitor, no differences were observed in the
expression of CD31 domain 1–5 (Figure 6B).
Discussion
The biological activity of CD31 is carried out by homophilic interac-
tion. During antigen presentation, the homophilic nature of CD31
facilitates lymphocyte engagement with other cells expressing CD31
such as antigen presenting cells (APCs), platelets and endothelial cells
(ECs). CD31 triggering modulates T-cell activation by inhibiting TCR
signalling. The shedding of CD31 Ig-like domain 1–5 prevents homo-
philic binding interaction and the consequent activation of CD31
ITIM/SHP2 inhibitory pathway.
CD31 plays an important immunoregulatory role by setting the
threshold for T-cell activation. Its involvement has been described in
several inflammatory diseases, including atherosclerosis and plaque
destabilization.8–13 CD4 þ T-cells from patients with ACS show an
enhanced response to TCR stimulation and a lower activation
threshold, at least partially caused by an enhanced amplification of
proximal TCR-mediated signals.3,21 The importance of the TCR
signal-strength in the differentiation of helper T-cell subsets has
increasingly been documented.22 A lower setting of the T-cell activa-
tion threshold could affect the T-cell differentiation fate, leading to an
imbalanced expansion of effector T-cell and regulatory T-cell subsets
observed in patients with ACS.3,23–25 The altered activity of proteins
involved in the modulation of upstream TCR signalling, such as
CD31, might modify the phosphorylation of downstream effectors
and finally the T-cell commitment. Moreover, CD31 signalling modu-
lates the overall expression of lineage-specifying transcription factors
for proinflammatory Th1 and Th17 cells, e.g. through modulation of
the Mitogen-activated protein kinases (MAPK) pathways.12
Our experiments suggested a role for MMP-9 in CD31 shedding, a
mechanism similar to that observed with other Ig-like transmem-
brane molecules. Notably, several studies have described high plasma
and serum levels of MMP-9 in patients with ACS.17–19 Moreover,
plasma MMP-9 concentration was identified as predictor of cardio-
vascular mortality in patients with symptomatic coronary artery
disease.19
Our study suggests that the reduced expression of the CD31 func-
tional domain 1–5 in patients with ACS as compared to SA patients
and CTRL might be at least partially mediated by MMP-9. Indeed, an
MMP-9-dependent enhanced cleavage of CD31 domain 1–5 might
promote excessive TCR activation thus influencing T-cell homeosta-
sis (Take home figure). Loss of CD31 Ig-like domain 1–5 prevents the
activation of CD31 ITIM/SHP2 inhibitory pathways. The consequent
reduction of CD31 signalling might lead to uncontrolled T-cell activa-
tion and altered naı̈ve T-cells differentiation.8,9,12 This is confirmed by
our observation that CD4þ T-cells from SA patients incubated with
serum from ACS patients exhibit reduced expression of CD31 func-
tional domain 1–5, which is prevented by MMP-9 inhibition. These
findings suggest a possible autocrine effect of MMP-9 on activated
CD4þ T-cells, which further amplifies their activation by generating a
positive feedback. In alternative, the effect of MMP-9 on CD4þ T-cell
activation might provide an additional link between innate and adap-
tive immunity in ACS. Indeed, this metalloprotease is produced by
several cell populations including monocytes, lymphocytes, and ECs
that might contribute to the overall bulk of plasma MMP-9. Overall,
the higher expression of this protein could affect coronary stability
not only by promoting plaque fissuring as previously described26,27
but also by increasing T-cell activation and by promoting T-cell differ-
entiation towards a pro-inflammatory phenotype. Moreover, MMP-9
expression in ECs is transcriptionally regulated in response to shear
stress.28 CD31 acts as mechanosensor that mediates EC responses
to shear stress and ECs are able to act as antigen-presenting-cells.29
Figure 6 Role of circulating matrix metalloproteinase-9 in CD31 cleavage. CD31 domain 1–5 surface expression on CD4þ T-cells from five stable
angina (left panel, green histograms) and from five acute coronary syndrome patients (right panel, red histograms). CD4þ T-cells were incubated for
24 h with serum obtained from acute coronary syndrome or stable angina patients in presence or absence of matrix metalloproteinase-9 inhibitor I.
Only CD4þ T-cells from stable angina incubated with acute coronary syndrome serum showed a significant reduction of CD31 domain 1–5. This
effect was prevented by the addition of matrix metalloproteinase-9 inhibitor I. Data are presented as mean 95% CI. MFI, median fluorescence
intensity.
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Thus, MMP-9 expression might also be critical during T cell–EC inter-
action, by modulating CD31 expression, and thus providing a further
link between the immune system and the vascular wall. Notably, T-
cells can stimulate MMP-9 endothelial production through a CD40-
CD40L contact-dependent mechanism.30 This process might further
affect the CD31 expression, and thus contribute to T-cell hyper-
reactivity in the atherosclerotic plaque.
Limitations
This study has several limitations. Indeed, it was a prospective observa-
tional analysis that included a limited number of patients. No power cal-
culation could be performed because of a lack of previous studies in this
setting; these limitations imply that several variables other than the cor-
onary disease state might explain the differences observed across these
three small populations. Indeed, differences regarding gender, smoke,
and diabetes that are known to influence MMP-9 expression were
found among the groups. However, our results seem to suggest that
those factors, as well as others increasing MMP-9 levels, might influence
plaque stability in ACS also through MMP-9, by determining the cleav-
age and shedding of the functional CD31 domain 1–5 on CD4þ T-cells.
Importantly, we were unable to determine a cause–effect relationship.
To this regard, we cannot exclude that loss of CD31 and the higher
production of MMP-9 might be part of the general stress response in
the acute setting of ACS. Moreover, although our experiments with
MMP-9 inhibitor suggest a role for this protease in CD31 cleavage,
other shedding mechanisms cannot be excluded.
In this study, we did not evaluate MMP-9 total activity in cell super-
natant. However, our inhibition experiments showed a significant
recovery of CD31 domain 1–5 by the addition of MMP-9 inhibitor I,
suggesting an increased activity of this metalloprotease. Finally, we
have not had the opportunity to collect coronary plaque specimens
in ACS and SA patients, thus losing information on the role of CD31
on T-cell locally resident in unstable plaques.
Although the coronary plaque characteristics were not assessed in
this study, our results introduce a new role for MMP-9 in adaptive
immunity dysregulation widely described in ACS3,23–25 and provide
novel insights into the mechanisms responsible for coronary instabil-
ity. Taken together the results of this study and of our previous stud-
ies on this topic,12,13 we propose the following sequence of events in
patients with ACS and systemic evidence of inflammation: MMP-9,
released by innate immunity cells and by T-cells, causes the cleavage
of CD31 domain 1–5; the increased expression of MMP-9 might
affect TCR-dependent T-cell activation and induce T-cell hyper-reac-
tivity, through the alteration of cellular pathways linked to CD31
cleavage (Take home figure).
Supplementary material
Supplementary material is available at European Heart Journal online.
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